Presentation to include clinical data from Aronora's phase 2 study of AB002, a first-in-class protein C activator enzyme that is being developed for the treatment and prevention of thrombotic and inflammatory diseases.

Presentation to include clinical data from Aronora's phase 2 study of AB023, a factor XI-targeted antibody that is being developed for the treatment and prevention of thrombosis and inflammation.

Enzyme that selectively targets blood clots has received FDA Fast Track designation, allowing for expedited clinical development

If not removed within 30-45 days, a dangerously high rate of so-called retrievable IVC filters, generally implanted to prevent pulmonary embolisms, experience complications that can lead to additional medical procedures, serious injury and death, and the risk generally outweighs any benefit, according to Ford and Associates Nationwide Legal Services.

The controversial devices are linked to at least 27 deaths and over 300 additional injuries. Many devices can become difficult or impossible to retrieve if left in for more than 30-45 days after implant.

A recent three part NBC News Investigation has raised serious concerns regarding the safety and FDA Approval Process of some IVC Filters.

A Minnesota author and ex-cop highlights the differences between how men and women handle communication about a crisis in his new memoir - an Amazon.com Bestseller Hot 100 New Release.

Recounting his startling true experiences in a new memoir -- an Amazon.com Bestseller Hot 100 New Release - a Minnesota author challenges current research on how much dogs are consciously aware of human needs.